Potential predictors of immunotherapy in small cell lung cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F23%3A10157929" target="_blank" >RIV/00098892:_____/23:10157929 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/23:A2402L0O RIV/61989592:15110/23:73619939

Výsledek na webu

<a href="https://www.por-journal.com/articles/10.3389/pore.2023.1611086/full" target="_blank" >https://www.por-journal.com/articles/10.3389/pore.2023.1611086/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/pore.2023.1611086" target="_blank" >10.3389/pore.2023.1611086</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Potential predictors of immunotherapy in small cell lung cancer

Popis výsledku v původním jazyce

Lung cancer is one of the leading causes of cancer-related deaths worldwide, with small cell lung cancer (SCLC) having the worst prognosis. SCLC is diagnosed late in the disease&apos;s progression, limiting treatment options. The most common treatment for SCLC is chemotherapy. As the disease progresses, immunotherapy, most commonly checkpoint inhibitor medication, becomes more important. Efforts should be made in the development of immunotherapy to map specific biomarkers, which play a role in properly assigning a type of immunotherapy to the right cohort of patients, where the benefits outweigh any risks or adverse effects. The objective of this review was to provide a thorough assessment of current knowledge about the nature of the tumor process and treatment options for small cell lung cancer, with a focus on predictive biomarkers. According to the information obtained, the greatest potential, which has already been directly demonstrated in some studies, has characteristics such as tumor microenvironment composition, tumor mutation burden, and molecular subtyping of SCLC. Several other aspects appear to be promising, but more research, particularly prospective studies on a larger number of probands, is required. However, it is clear that this field of study will continue to expand, as developing a reliable method to predict immunotherapy response is a very appealing goal of current medicine and research in the field of targeted cancer therapy.

Název v anglickém jazyce

Potential predictors of immunotherapy in small cell lung cancer

Popis výsledku anglicky

Lung cancer is one of the leading causes of cancer-related deaths worldwide, with small cell lung cancer (SCLC) having the worst prognosis. SCLC is diagnosed late in the disease&apos;s progression, limiting treatment options. The most common treatment for SCLC is chemotherapy. As the disease progresses, immunotherapy, most commonly checkpoint inhibitor medication, becomes more important. Efforts should be made in the development of immunotherapy to map specific biomarkers, which play a role in properly assigning a type of immunotherapy to the right cohort of patients, where the benefits outweigh any risks or adverse effects. The objective of this review was to provide a thorough assessment of current knowledge about the nature of the tumor process and treatment options for small cell lung cancer, with a focus on predictive biomarkers. According to the information obtained, the greatest potential, which has already been directly demonstrated in some studies, has characteristics such as tumor microenvironment composition, tumor mutation burden, and molecular subtyping of SCLC. Several other aspects appear to be promising, but more research, particularly prospective studies on a larger number of probands, is required. However, it is clear that this field of study will continue to expand, as developing a reliable method to predict immunotherapy response is a very appealing goal of current medicine and research in the field of targeted cancer therapy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

<a href="/cs/project/NU21-03-00372" target="_blank" >NU21-03-00372: Malé vazebné proteiny cílené na proteiny imunitní kontrolní dráhy PD-1/PD-L1 jako nové diagnostické nástroje</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pathology &amp; Oncology Research

ISSN

1219-4956

e-ISSN

1532-2807

Svazek periodika

29

Číslo periodika v rámci svazku

May

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

12

Strana od-do

1611086

Kód UT WoS článku

000989074500001

EID výsledku v databázi Scopus

2-s2.0-85159662099